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Preoperative carcinoembryonic antigen is related to
tumour stage and long-term survival in colorectal
cancer
MAS Chapman', D Buckley', DB Henson2 and NC Armitage'
'Department of Surgery and "-Clinical Chemistry. University Hospital. Queens Medical Centre. Nottingham NG7 2UH. UK
Summary Evidence as to the value of preoperative carcinoembryonic antigen (CEA) in guiding treatment for patients with colorectal cancer
is conflicting. The aim of this prospective study was to investigate the value of preoperative CEA in predicting tumour factors of proven
prognostic value and long-term survival in patients undergoing surgery for colorectal cancer. Preoperative serum CEA, tumour ploidy. stage
and grade were ascertained in 277 patients undergoing colorectal cancer surgery. This cohort of patients were followed up for a minimum of
5 years. or until death, in a dedicated colorectal clinic. Patients with an elevated CEA had a 5 year survival of 39%. This increased to 570° if
the CEA was normal (P = 0.001). The proportion of patients with a raised CEA increased with a more advanced tumour stage (P < 0.000001)
and a poorly differentiated tumour grade (P < 0.005). Once stage had been controlled for, CEA was not a predictor of survival. No relationship
between tumour ploidy and CEA was found. In conclusion, a raised preoperative serum CEA is likely to be associated with advanced tumour
stage and poor long-term survival, compared with patients with a normal value.
Keywords: colorectal cancer; carcinoembryonic antigen; survival
As the treatment of colorectal cancer has become more sophisti-
cated. the aim ofthe surgeon is to tailor surgical and adjuvant treat-
ment for each patient. The lack of reliable parameters of prox-en
prognostic xalue is a limitation to preoperative planning. The Xalue
of preoperative carcinoembrx onic antigen (CEA) as a prognostic
indicator in patients with resectable colorectal cancer is conflictinc
(Eskelinen et al. 1994: Northover. 1995: Carpelan-Holmstrom et al.
1996).,with some studies reporting that it is of value. especialix for
the more locallv advanced tumour. whereas others have been
unable to show that preoperatixe CEA is an independent predictor
of sunix-al (Filella et al. 1994: Wang et al. 1994 .
A'e have prexiouslx shown that the ploidy status of stage B
colorectal tumours is an independent prognostic marker of
survival (Chapman et al. 1995). It may be speculated that cells
x ith an abnormal amount of nuclear DNA (aneuploid) may
produce abnormal quantities of CEA compared with cells with a
normal quantity of nuclear DNA (diploid). In one study. 48% (36
of 75) ofpatients wxith an aneuploid tumour had a raised preopera-
tixe CEA compared with 34% (14 of 41) of patients with diploid
tumours (P < 0.05). Patients with aneuploid tumours had an
elexated CEA in 38% ofstage A and B disease and 61% in stage C
and D disease (Kouri et al. 1991)
The aim of this prospectixe studv A-as to inxestigate the rela-
tionship between tumour ploidy and serum CEA measured pre-
operatixely in patients undergoing surgerv for colorectal cancer
and to assess Ahether these xalues predicted tumour stage. degree
ofdifferentiation or long-term cancer-free sun-ix-al.
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PATIENTS AND METHODS
Serum CEA was measured preoperatix vel in 277 patients
undergroing colon and rectal cancer resections in the Department
of Surgery. Unix ersity Hospital. Nottingham. UK. betw-een
November 1982 and March 1988. The pathological stage was taken
according to Dukes' method (Dukes. 1932). to which a stage D xxas
added for patients with distant metastases or those with knowxn
residual local tumour. Histological grade was defined as poorlx
differentiated or well/moderately differentiated as recommended
bv the UKCCR working party on the staging of colorectal cancer
Williams et al. 1988). Serum CEA wxas measured using the Serono
Bridae Kit. wxhich utilizes tx-o monoclonal antibody--coated tubes
and '-I as a radiolabel. The upper himit of normal in our laborator-
is 10 igc 1-'. Tumour cell DNA content wxas measured in both fresh
and paraffin-embedded tissue as previously described (Armitage et
al. 1991). Briefly. haxing prepared single-cell suspensions. the
nuclei from the fresh tissue were stained with propidium iodide and
those from paraffin-embedded tissue ith 4'.6'-diaminido. 2-
phenvl indole hydrochloride (Boehringer Corporation. Lewes.
Sussex. UK). A DNA index was calculated as the ratio of the fluo-
rescent intensitx of the GU/G, peak of the tumour cells compared
xxith that forthe G /G-, peak ofthe diploid cells. A peak ith a DNA
index greater than 1.1 that contained at least 10% of the total cells
was classed as an aneuploid tumour. 'When the DNA index xas
bets een 1.9 and 2.1. the tumour xx-as classed as tetraploid.
A colonic tumour proximal to the splenic flexure x-as classified
as rinht-sided and those between the splenic flexure and rectosig-
moid junction as left-sided. Tumours distal to the rectosigmoid
junction were considered to be rectal. None of the patients were
offered adjuvant chemotherapy and. on the basis of familx historx.
none suffered from hereditarx non-polyposis colon cancer
(H.NPCC). After discharge from hospital. patients were regularly
followxed up in a speciallv constituted colorectal cancer clinic for a
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Table 1 Tumour stage, grade and preoperative CEA levels in patients undergoing colorectal cancer surgery (%)
Stage Number of CEA < 10 CEA > 10 Well/moderately Poorly
patients gg ml-' ,g ml-' differentiated differentiated
A 37 (13) 34 (92) 3 (8) 36 (97) 1
B 128 (46) 103 (80) 25 (20) 114 (89) 14
C 69 (25) 51 (74) 18 (26) 55 (80) 14
D 43 (16) 14 (33) 29 (67) 34 (79) 8
Table 2 Tumour site, grade and preoperative CEA levels in patients undergoing colorectal cancer surgery (%)
Right-sided Left-sided Rectum Well/moderately Poorly
differentiated differentiated
CEA . 10 ig ml-' 38 (19) 88 (44) 76 (37) 182 (90) 20 (10)
CEA > 10 ,ug ml-1 23 (31) 35 (46) 17 (23) 58 (77) 17 (23)
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Figure 1 Effect of tumour stage on long-term survival. Log rank 151; df = 3;
P< 0.00001
minimum of 5 years or until death. Follow-up included clinical
and endoscopic examinations. Patients with clinical suspicion of
recurrence were investigated as appropriate by endoscopy, radi-
ology including magnetic resonance imaging and immunoscintig-
raphy. If the cause of death was unknown, a post-mortem was
performed to seek evidence ofrecurrent disease.
Statistical analysis was by chi-squared test and Kaplan-Meir
plots (SPSS Inc, Chicago, II, USA). In the analysis of survival,
patients who died of non-colorectal cancer-related illness were
censored from analysis at time ofdeath. The results are expressed
in terms of cancer-specific survival. Statistical significance was
taken at P < 0.05.
RESULTS
Two hundred and eighty-six patients were entered into this study
and nine (3%) deaths occurred within 30 days of surgery. These
patients have been excluded from the analysis as this reflects
surgical morbidity rather than tumour characteristics. The median
age of patients at entry to this study was 67 (range 40-87) years.
None was lost to follow-up. The median survival was 50 months,
with a range of 1-126 months.
The tumour stage, distribution, number ofpatients with a raised
preoperative CEA and histological grade of the 277 tumours are
shown in Table 1.
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Figure 2 Effect of preoperative serum CEA level on long-term colorectal
cancer survival. Log rank 16.11; P= 0.0001
Two hundred and two (73%) patients had a preoperative CEA
< 11 gg ml-'. The number of patients with a raised preoperative
CEA tended to increase with a more advanced tumour stage (chi-
squared test, P < 0.000001), and patients with a poorly differenti-
ated tumour were more likely to have a raised preoperative CEA
level than those with a well/moderately differentiated tumour (chi-
squared test, P < 0.005, Table 2).
Previous work has suggested that tumours having a tetraploid
DNA content behave in a similarfashion to diploid tumours and so
have been considered together (Chapman et al, 1995). One
hundred and twenty-two (44%) of the tumours were diploid or
tetraploid and the remaining 155 were aneuploid. Ninety (74%) of
the 122 patients with a diploid tumour had a preoperative CEA
<11jIg ml-' compared with 112 (72%) ofthe 155 patients with an
aneuploid tumour.
The site ofthe tumours was not related to an elevated CEA level
(Table 2). Interestingly, of the 164 men in the study, only 23 had
right-sided tumours compared with 32 out of 113 tumours in
women (chi-squared test, P < 0.005).
The overall cancer-specific survival for these patients was 52%.
If those undergoing palliative surgery (stage D tumours) are
excluded, the cancer-specific survival rises to 62%.
The colorectal cancer-specific survival curves for stages A,B,C
and D are shown in Figure 1 and, as expected, there is a highly
statistically significant difference between the curves. Patients
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with a raised preoperati-e CEA had a -orse 5-year survival (39c)
than those w-ith a normal preoperatixe CEA (57%7r) (Ftaure 2:
hazard ratio 2.04: 95%7- confidence intervals 1.4-2.9: log rank test
P = 0.0001). How-ever. when tumour staae was controlled for. the
survival benefit of a low- preoperative CEA was lost (hazard ratio
1.28: 95%/c confidence intervals 0.87-1.88: log rank test P = 0.20).
DISCUSSION
Carcinoembrvonic antigen (CEA) was first characterized by Gold
and Freedman in 1965. It was thought to be produced by carcino-
matous or embrvonic tissue and not normal adult tissue. However.
it soon became apparent that high circulating levels of CEA could
be found in non-malignant adult diseases and was capable ofbeing
produced by normal adult cgastro intestinal secretar- cells. Despite
this. in 1974 the United States Food and Drug Administration
approved marketing ofserum CEA levels for the early detection of
cancer and screening of patients at hiah risk of developing
colorectal cancer. Since then. the benefit of measuring preopera-
tive serum CEA has been controversial. with different groups
reaching different conclusions (Moertel et al. 1986).
Wanebo et al (1978) studied 358 patients with colorectal cancer
and found that the recurrence rate was higher in patients with
Dukes' B and C lesions iftheir preoperative CEA was greater than
5 ng ml-'. this was hiahl1v statistically significant within the two
stages. Thev also found a linear correlation bet-een preoperatiVe
CEA levels and estimated mean recurrence time. In contrast to
this. Goslin et al. (1980) found no correlation between preopera-
tive CEA levels and risk of tumour recurrence in 71 stage B
tumours. but there was a highly significant correlation between
CEA levels and recurrence in 46 patients with stage C tumours.
Interestingly. if the poorly differentiated stage C tumours are
removed. this difference in recurrence rates becomes even more
sianificant. They suggested that poorly differentiated tumours
produce little tissue CEA. and this is reflected in low serum CEA
levels. However. this study has been unable to confirm this obser-
vation: rather an elevated CEA was associated with poorly differ-
entiated tumours.
Lewi et al ( 1984) obtained similar results to Goslin et al ( 1980):
102 patients with stage C tumours and a preoperati-e CEA level
grreater than 100 prg 1-' (equivalent to 40 igo ml-' in Goslin's study)
showed a sianificantly decreased 2- and 5-vear survival compared
with those with a lower CEA. They found no correlation between
preoperative CEA and disease-free survival for stage B tumours.
Moertel et al (1986) measured preoperative CEA in 316 patients
undergoing surgery for colorectal cancer and obtained complete 5-
year follow-up. Preoperative CEA levels were significantly corre-
lated with stage ofdisease and with the size ofthe primarv tumour
in stagye B tumours. There was no association between preopera-
tive CEA and survival for stage A. B or C tumours with 1-3 nodes
involved. However. it was an independent predictor of survival in
patients whose tumours had four or more metastaticallv involved
lymph nodes. This finding. which is similar to our results. has also
been confirmed by Filella et al (1992). Others usin, a panel of
serum markers including CEA measured preoperatively have also
been unable to show any benefit over Dukes' staginc in predictingy
survival (Diez et al. 1994: Lindmark et al. 1995).
In contrast. the Japanese report a different experience regarding
the ability of preoperative CEA level to predict survival. indepen-
dent of tumour stace. Multivariate analysis on data pooled from
1254 patients w-ith colorectal cancer revealed that an elevated
preoperative CEA as well as nodal involvement and -enous inva-
sion were independent factors affecting disease-free survival
(Takahashi et al. 1996). Tsuchiva et al (1994). in a series of 124
patients w-ith colorectal cancer. found that the most significant
discriminant in prognosis was liver metastasis followed by pre-
operative CEA level. depth of invasion and DNA ploidy pattern.
In the study reported here. the distribution of tumour stage and
cancer-free survival is similar to that reported in other large series.
Patients w-ith a raised preoperative CEA have a worse prognosis
than those with a normal value. Like many other studies. a rela-
tionship between increasing preoperative serum CEA and more
advanced tumour stage was found. However. once stage had been
controlled for. preoperative CEA gave no useful prognostic infor-
mation. It is unlikely that a significant effect of a raised CEA on
prognosis has been missed. as this study has a power of 80%7e in
detecting a 1.2 difference in the hazard ratios between the groups
at the 5%7 level.
This study also found that a poorly differentiated tumour was
associated with a raised preoperative CEA. However. rather
surprisingly. there was no relationship bet-een tumour ploidy and
CEA level. This finding is in contrast to those of Kouri et al
(1991). This mav be because serum CEA levels tend to reflect
tumour bulk rather than differences in cell production.
This studv confirms the findings of other workers in the West
that the measurement ofpreoperative CEA is oflittle added help in
predicting survival once the Dukes' stage is known. Whether this
holds true for colorectal cancer in the Far East remains to be seen.
and it may be fruitful to explore whether this discrepancv reflects
biological differences in the behaviour of colorectal cancer.
Occasionally. small early tumours are excised by endoscopic
means. such as transanal endoscopic microsurgaerv (TENIS).and a
raised preoperative CEA measurement in this group of patients
may indicate advanced local or disseminated disease. allowing
treatment to be tailored to the tumourstage. However. preoperative
CEA measurement is of no benefit in predicting surviVal when
radical surgaical excision of the tumour is planned. Whether its
measurement is of anx use in the follow-up of patients who have
undergone potentially curative colorectal cancer is a contentious
issue. but there are no data to indicate that its measurement allows
earlier detection of tumour recurrence and increases patient
survival (McCall et al. 1994: Vauthev et al. 1996).
This study concludes that a raised preoperative serum CEA is
associated with a poorer proanosis and more advanced tumour
stage but is of little value in predicting, patient survival once the
Dukes' staae is known.
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